Kiniksa Announces Phase 2 Clinical Trial of Vixarelimab (KPL-716) in Prurigo Nodularis Meets Primary Efficacy Endpoint

– Statistically significant primary efficacy endpoint of reduction in weekly-average Worst-Itch Numeric Rating Scale (WI-NRS) at Week 8 –
– Statistically significant secondary efficacy endpoint of improvement in prurigo nodularis-investigator’s global assessment (PN-IGA) 0/1 at Week 8 –
Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search